John Dylan Spalding

John Dylan Spalding

Auto-generated profile, based on publicly available information

John Dylan Spalding

European Bioinformatics Institute, European Molecular Biology Laboratory, Wellcome Genome Campus, Hinxton, Cambridge, UK

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 June 2015 in Nature Genetics
Verified
Journal Article
Open access
PDF file
ILIlkka Lappalainen
Ilkka Lappalainen
JAJeff Almeida-King
Jeff Almeida-King
VKVasudev Kumanduri
Vasudev Kumanduri
ASAlexander Senf
Alexander Senf
JSJohn Dylan Spalding
John Dylan Spalding
PFPaul Flicek
Paul Flicek
Paul Flicek and colleagues provide an update on the European Genome-phenome Archive (EGA), a service of the European Bioinformatics Institute (EMBL-EBI) and the Center for Genome Regulation (CRG). The authors describe the EGA policies and infrastructure, how access decisions are made, methods for data submission and future plans for expansion of this database. The European Genome-phenome Archive (EGA) is a permanent archive that promotes the distribution and sharing of genetic and phenotypic data consented for specific approved uses but not fully open, public distribution. The EGA follows strict protocols for information management, data storage, security and dissemination. Authorized access to the data is managed in partnership with the data-providing organizations. The EGA includes major reference data collections for human genetics research.

10 November 2021 in Cell Genomics
Verified
Journal Article
Open access
HHeidi Rehm
Heidi Rehm
APAngela J.H. Page
Angela J.H. Page
LSLindsay Smith
Lindsay Smith
JAJeremy B. Adams
Jeremy B. Adams
GAGil Alterovitz
Gil Alterovitz
EBEwan Birney
Ewan Birney
The Global Alliance for Genomics and Health (GA4GH) aims to accelerate biomedical advances by enabling the responsible sharing of clinical and genomic data through both harmonized data aggregation and federated approaches. The decreasing cost of genomic sequencing (along with other genome-wide molecular assays) and increasing evidence of its clinical utility will soon drive the generation of sequence data from tens of millions of humans, with increasing levels of diversity. In this perspective, we present the GA4GH strategies for addressing the major challenges of this data revolution. We describe the GA4GH organization, which is fueled by the development efforts of eight Work Streams and informed by the needs of 24 Driver Projects and other key stakeholders. We present the GA4GH suite of secure, interoperable technical standards and policy frameworks and review the current status of standards, their relevance to key domains of research and clinical care, and future plans of GA4GH. Broad international participation in building, adopting, and deploying GA4GH standards and frameworks will catalyze an unprecedented effort in data sharing that will be critical to advancing genomic medicine and ensuring that all populations can access its benefits.

26 November 2012 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
ILIlkka Lappalainen
Ilkka Lappalainen
JLJohn Lopez
John Lopez
LSLisa Skipper
Lisa Skipper
THTimothy Hefferon
Timothy Hefferon
JSJ. Dylan Spalding
J. Dylan Spalding
DCDeanna M. Church
Deanna M. Church
Much has changed in the last two years at DGVa (http://www.ebi.ac.uk/dgva) and dbVar (http://www.ncbi.nlm.nih.gov/dbvar). We are now processing direct submissions rather than only curating data from the literature and our joint study catalog includes data from over 100 studies in 11 organisms. Studies from human dominate with data from control and case populations, tumor samples as well as three large curated studies derived from multiple sources. During the processing of these data, we have made improvements to our data model, submission process and data representation. Additionally, we have made significant improvements in providing access to these data via web and FTP interfaces.

9 May 2017 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
YPYasset Perez-Riverol
Yasset Perez-Riverol
MBMingze Bai
Mingze Bai
FLFelipe da Veiga Leprevost
Felipe da Veiga Leprevost
SSSilvano Squizzato
Silvano Squizzato
YPYoung Mi Park
Young Mi Park
HHHenning Hermjakob
Henning Hermjakob

14 December 2017 in BMJ Open
Verified
Journal Article
Open access
PDF file
COChristian Ohmann
Christian Ohmann
RBRita Banzi
Rita Banzi
SCSteve Canham
Steve Canham
SBSerena Battaglia
Serena Battaglia
MMMihaela Matei
Mihaela Matei
JDJacques Demotes-Mainard
Jacques Demotes-Mainard
Objectives We examined major issues associated with sharing of individual clinical trial data and developed a consensus document on providing access to individual participant data from clinical trials, using a broad interdisciplinary approach. Design and methods This was a consensus-building process among the members of a multistakeholder task force, involving a wide range of experts (researchers, patient representatives, methodologists, information technology experts, and representatives from funders, infrastructures and standards development organisations). An independent facilitator supported the process using the nominal group technique. The consensus was reached in a series of three workshops held over 1 year, supported by exchange of documents and teleconferences within focused subgroups when needed. This work was set within the Horizon 2020-funded project CORBEL (Coordinated Research Infrastructures Building Enduring Life-science Services) and coordinated by the European Clinical Research Infrastructure Network. Thus, the focus was on non-commercial trials and the perspective mainly European. Outcome We developed principles and practical recommendations on how to share data from clinical trials. Results The task force reached consensus on 10 principles and 50 recommendations, representing the fundamental requirements of any framework used for the sharing of clinical trials data. The document covers the following main areas: making data sharing a reality (eg, cultural change, academic incentives, funding), consent for data sharing, protection of trial participants (eg, de-identification), data standards, rights, types and management of access (eg, data request and access models), data management and repositories, discoverability, and metadata. Conclusions The adoption of the recommendations in this document would help to promote and support data sharing and reuse among researchers, adequately inform trial participants and protect their rights, and provide effective and efficient systems for preparing, storing and accessing data. The recommendations now need to be implemented and tested in practice. Further work needs to be done to integrate these proposals with those from other geographical areas and other academic domains.

4 March 2019 in Nature Biotechnology
Verified
Journal Article
Open access
PDF file
MFMarc Fiume
Marc Fiume
MCMiroslav Cupak
Miroslav Cupak
SKStephen Keenan
Stephen Keenan
JRJordi Rambla
Jordi Rambla
STSabela de la Torre
Sabela de la Torre
SSSerena Scollen
Serena Scollen